Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 85Carcinoma, Non-Small-Cell Lung 75Breast Neoplasms 73Recurrence 64Colorectal Neoplasms 62Pancreatic Neoplasms 59Multiple Myeloma 57Melanoma 56Carcinoma, Hepatocellular 56Advanced Solid Tumor 55Leukemia, Myeloid, Acute 53Advanced Solid Tumors 53Lymphoma 52Neoplasm Metastasis 50Stomach Neoplasms 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Solid Tumor 39Lymphoma, B-Cell 39Ovarian Neoplasms 38Lymphoma, Non-Hodgkin 37Lung Neoplasms 35Glioblastoma 35Prostatic Neoplasms 34Leukemia 28Head and Neck Neoplasms 27Leukemia, Lymphocytic, Chronic, B-Cell 26Uterine Cervical Neoplasms 25Burkitt Lymphoma 24Esophageal Neoplasms 22Urinary Bladder Neoplasms 18

Interventions

repaglinide 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unknown × Prostate Cancer Patients × Clear all
NCT04664725 2020-12-11

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
18 enrolled
Genitourinary

Prostate Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡